ASND · Ascendis Pharma A/S

This 6-K filing updates Ascendis Pharma A/S’s Articles of Association to reflect the current status of its equity-related authorizations and historical warrant activity. The core disclosure is administrative and governance-focused—not operational or financial—centering on the expiration of the Article 4a warrant authority in 2018 and the continued validity of warrants previously issued under it, alongside active, time-bound authorities for future capital increases and convertible debt. The filing confirms that as of 12 May 2026, over 13.5 million warrants have been issued across multiple authorizations, with more than 8.7 million no longer outstanding due to exercise, lapse, or annulment. Importantly, the Board has actively used the Article 4f authorization—issuing 125,307 warrants in five tranches from December 2023 through April 2025—each tied to specific USD-based exercise prices converted to DKK using the exchange rate on the exercise day. These actions support long-term employee and management alignment but do not trigger immediate dilution. The presence of multiple concurrent capital increase authorities—including pre-emptive and non-pre-emptive options, as well as convertible bond capacity—provides the company flexibility for future financing or strategic initiatives, though no new issuances are announced in this filing. For investors, this represents a routine corporate housekeeping update with medium materiality: it clarifies existing structural capabilities and historical equity activity but introduces no new events, financial results, executive changes, or strategic transactions.